Table 2 Types and management of antithrombotic agents in patients injected with epinephrine–saline (Group A) or hypertonic saline (Group B) for colorectal endoscopic mucosal resection (EMR)
| Â | Group A | Group B | P value |
|---|---|---|---|
Number of antithrombotic agents | |||
 Single agent | 88 (86.3%) | 85 (83.3%) | 0.70 |
 Multiple agents | 14 (13.7%) | 17 (16.7%) |  |
Anticoagulants | 21 (20.6%) | 40 (39.2%) | 0.006 |
 Warfarin | 12 (11.8%) | 25 (24.5%) |  |
 DOAC | 9 (8.8%) | 14 (13.7%) |  |
Management before EMR | |||
 Cessation | 5 (5.0%) | 2 (2.0%) | 0.45 |
 Heparin replacement | 15 (14.7%) | 24 (23.5%) | 0.15 |
 DOAC replacement | 1 (1.0%) | 1 (1.0%) | 1.00 |
Antiplatelet agents | 85 (83.3%) | 69 (67.6%) | 0.014 |
 Aspirin | 36 (35.3%) | 40 (39.2%) |  |
 Clopidogrel | 20 (19.6%) | 12 (11.8%) |  |
 Ticlopidine | 6 (5.8%) | 1 (1.0%) |  |
 Cilostazol | 16 (15.7%) | 9 (8.8%) |  |
 Others | 7 (6.9%) | 7 (6.9%) |  |
Management before treatment | |||
 Cessation | 4 (3.9%) | 3 (2.9%) | 1.00 |
 Cilostazol replacement | 15 (14.7%) | 11 (10.8%) | 0.53 |